Turnstone biologics presents preclinical data highlighting potential for selected tumor-infiltrating lymphocyte (til) therapy in solid tumors at the 2024 society for immunotherapy of cancer (sitc) annual meeting

Turnstone's next-generation selected til technology is designed to selectively expand the most potent tumor-reactive t cells for treatment of solid tumors results further support the continued clinical advancement of tidal-01, currently being evaluated in phase 1 trials san diego, nov. 05, 2024 (globe newswire) -- turnstone biologics corp. (“turnstone” or the “company”) (nasdaq: tsbx), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (selected til) therapy, today announced it will be presenting two posters highlighting preclinical data on methods for til selection at the society for immunotherapy of cancer (sitc) 39th annual meeting being held november 6-10, 2024 in houston, texas. “we remain confident that delivering a til-based product with a higher proportion of tumor-reactive t cells is the key to extending the clinical application of tils across a broader range of solid tumors,” said david stojdl, ph.d.
TSBX Ratings Summary
TSBX Quant Ranking